

BAFNA PHARMACEUTICALS LIMITED


Regd office: 299, THAMBU CHETTY STREET, CHENNAI- 600 001

Statement of Standalone Unaudited Financial Results for the Quarter and 3 Months Ended 30 th June 2015

PART I							Rs. In Lakhs
Particulars	STANDALONE						
	3 months ended (30-06-2015)	Preceding 3 Months Ended (31-03-2015)	Corresponding 3 months ended in the previous year (30-06-2014)	Year to Date figures for current Period ended (30-06-2015)	Year to Date figures for the previous year ended (30-06-2014)	Previous Year Ended (31-03-2015)	
	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited	
1. Income form Operations							
(a) Net Sales/Income from Operations (net of excise duty)	2,311.98	1,937.40	3,522.64	2,311.98	3,522.64	10,140.94	
(b) Other Operating Income	-	(65.47)	-	-	-	4,111.07	
Total income from operations (net)	2,311.98	1,871.93	3,522.64	2,311.98	3,522.64	14,252.02	
2. Expenditure							
a. Cost of materials consumed	415.43	712.23	502.52	415.43	502.52	3,382.64	
b. Purchase of stock-in-trade	1,431.13	2,424.01	1,624.56	1,431.13	1,624.56	4,785.89	
c. Changes in inventories of finished goods,WIP and stock-in-trade	33.19	378.27	201.96	33.19	201.96	1,235.84	
d. Employees benefits expense	159.35	191.21	352.38	159.35	352.38	1,034.29	
e. Depreciation and amortisation expense	102.44	36.16	197.11	102.44	197.11	523.76	
f. Other expenditure (Any item exceeding 10% of the total expenses relating to continuing operations)	71.61	512.08	279.90	71.61	279.90	1,278.77	
Total Expenses	2,213.16	4,253.95	3,158.42	2,213.16	3,158.42	12,241.20	
3. Profit/(Loss) from Operations before Other Income, finance cost and Exceptional Items (1-2)	98.82	(2,382.02)	364.22	98.82	364.22	2,010.82	
4. Other Income	27.22	40.57	10.67	27.22	10.67	113.51	
5. Profit/(Loss) from ordinary activities before finance cost and Exceptional Items (3+/- 4)	126.04	(2,341.45)	374.88	126.04	374.88	2,124.33	
6. Finance Costs	237.87	268.92	332.89	237.87	332.89	1,247.63	
7. Profit/(Loss) from ordinary activities after finance cost but before Exceptional Items (5+/- 6)	(111.83)	(2,610.37)	42.00	(111.83)	42.00	876.71	
8. Exceptional items	-	-	-	-	-	268.81	
9. Profit / Loss from Ordinary Activities before tax (7+/- 8)	(111.83)	(2,610.37)	42.00	(111.83)	42.00	607.90	
10. Tax expense	7.44	(333.20)	11.06	7.44	11.06	(2.84)	
11. Net Profit / Loss from Ordinary Activities after tax (9 +/- 10)	(119.27)	(2,277.17)	30.94	(119.27)	30.94	610.73	
12. Extraordinary Item (net of tax expense Rs. ____ lacs)	-	-	-	-	-	-	
13. Net Profit/ Loss for the period (11 +/- 12)	(119.27)	(2,277.17)	30.94	(119.27)	30.94	610.73	
14. Share of profit/ (loss) of associates*	-	-	-	-	-	-	
15. Minority Interest*	-	-	-	-	-	-	
16. Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 +/- 14 +/- 15)*	(119.27)	(2,277.17)	30.94	(119.27)	30.94	610.73	
17. Paid up equity share capital (Face value of Rs.10/- each)	1,865.63	1,865.63	1,838.13	1,865.63	1,838.13	1,865.63	
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-	
19 (i). Earnings Per Share (EPS) (before extraordinary items) (not annualised)							
a) Basic	(0.64)	(12.21)	0.16	(0.64)	0.16	3.27	
b) Diluted	(0.64)	(12.21)	0.16	(0.64)	0.16	3.27	
19 (ii). Earning per share (after extraordinary items) (not annualised)							
a) Basic	(0.64)	(12.21)	0.16	(0.64)	0.16	3.27	
b) Diluted	(0.64)	(12.21)	0.16	(0.64)	0.16	3.27	



Part II Particulars	STANDALONE					
	3 months ended	Preceding 3 Months Ended	Corresponding 3 months ended in the previous year	Year to Date figures for current Period ended	Year to Date figures for the previous year ended	Previous year ended
	(30-06-2015)	(31-03-2015)	(30-06-2014)	(30-06-2015)	(30-06-2014)	(31-03-2015)
	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
A. Particulars of Shareholding						
1. Public Shareholding						
- No. of shares	11,892,412	11,805,566	11,831,332	11,892,412	11,831,332	11,805,566
- Percentage of shareholding	63.74	63.28	63.42	63.74	63.42	63.28
2. Promoters and promoter group shareholding**						
a) Pledged/Encumbered						
- Number of shares	1,397,736	1,397,736	1,530,000	1,397,736	1,530,000	1,397,736
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	20.66	20.40	22.42	20.66	22.42	20.40
- Percentage of shares (as a% of the total share capital of the Company)	7.49	7.49	8.20	7.49	8.20	7.49
b) Non-encumbered						
- Number of Shares	5,366,187	5,453,033	5,295,003	5,366,187	5,295,003	5,453,033
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	79.34	79.60	77.58	79.34	77.58	79.60
- Percentage of shares (as a% of the total share capital of the company)	28.76	29.23	28.38	28.76	28.38	29.23

NOTES									
1	The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 12.08.2015								
2	<p>Status of Investor Complaints:</p> <table border="0"> <tr> <td>Opening balance</td> <td>Nil</td> </tr> <tr> <td>Pending at the beginning of the quarter</td> <td>Nil</td> </tr> <tr> <td>No. of complaints received and disposed off during the quarter</td> <td>Nil</td> </tr> <tr> <td>Complaints pending at the end of the quarter</td> <td>Nil</td> </tr> </table>	Opening balance	Nil	Pending at the beginning of the quarter	Nil	No. of complaints received and disposed off during the quarter	Nil	Complaints pending at the end of the quarter	Nil
Opening balance	Nil								
Pending at the beginning of the quarter	Nil								
No. of complaints received and disposed off during the quarter	Nil								
Complaints pending at the end of the quarter	Nil								
3	The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.								
4	The Limited Review as required under Clause 41 of the Listing Agreement has been completed by the statutory Auditors for the Quarter ended 30.06.2015								
5	The Company is following Depreciation as provided in the Part C of Schedule II of the Companies Act 2013.								
6	The MD and Manager-Accounts & Finance certificate in respect of the above results in terms of the requirement of Clause 41 of the Listing Agreement has been placed before the Board of Directors.								
7	The figures of the Quarter are the balancing figures in respect of the Financial year and the published year to date figures upto the first quarter of the Financial year.								
	<p>For BAFNA PHARMACEUTICALS LIMITED</p>  BAFNA MAHAVEER CHAND MANAGING DIRECTOR								
Place :	Chennai								
Date :	12/08/2015								

